Researcher
Gil Awada
- Keywords:Medicine
- Disciplines:Natural sciences, Engineering and technology, Social sciences
Affiliations
- Medical Oncology (Department)
Member
From1 Sep 2023 → Today - Laboratory for Medical and Molecular Oncology (Research group)
Member
From22 Mar 2021 → Today - Clinical sciences (Department)
Member
From15 Nov 2023 → Today - Clinical sciences (Department)
Member
From15 Nov 2023 → 15 Nov 2023 - Medical Oncology (Department)
Member
From1 Nov 2021 → 31 Jul 2023 - Internal medicine (Department)
Member
From1 Sep 2021 → 31 Oct 2021 - Medical Oncology (Department)
Member
From1 Aug 2021 → 31 Aug 2021 - Clinical sciences (Department)
Member
From8 Apr 2019 → 31 Jul 2021 - Clinical sciences (Department)
Member
From1 Oct 2017 → 31 Jul 2021 - Faculty of Medicine and Pharmacy (Faculty)
Member
From13 Jul 2017 → 18 Jun 2021 - Internal medicine (Department)
Member
From1 Aug 2016 → 31 Jul 2021 - Faculty of Medicine and Pharmacy (Faculty)
Member
From4 Oct 2015 → 27 Apr 2023 - Faculty of Medicine and Pharmacy (Faculty)
Member
From1 Aug 2011 → 24 Jun 2015
Publications
11 - 20 of 37
- Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy(2021)
Authors: Jens Tijtgat, Julia Katharina Schwarze, Gil Awada, Bart Neyns, Sandrine Aspeslagh
Pages: 272-276 - A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT)(2021)
Authors: Gil Awada, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Hendrik Everaert, Bart Neyns
- Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome(2021)
Authors: Sim Vermeulen, Gil Awada, Marleen Keyaerts, Bart Neyns, Hendrik Everaert
Pages: 1630-1640 - Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse(2021)
Authors: Yanina Jansen, Inneke Willekens, Teofila Seremet, Gil Awada, Julia Katharina Schwarze, Johan De Mey, Carola Brussaard, Bart Neyns
Pages: 1-13 - A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab(2021)
Authors: Gil Awada, Yanina Jansen, Julia Katharina Schwarze, Jens Tijtgat, Lennert Hellinckx, Odrade Gondry, Sim Vermeulen, Sarah Warren, Kelly A Schats, Pieter-Jan van Dam, et al.
Pages: 1-18 - Immune Checkpoint Inhibitor Therapy for ACTH-Secreting Pituitary Carcinoma(2021)
Authors: Bastiaan Sol, Jeroen M.K. de Filette, Gil Awada, Steven Raeymaeckers, Sandrine Aspeslagh, Corina Andreescu, Bart Neyns, Brigitte Velkeniers-Hoebanckx
Pages: 1-5 - Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors(2020)
Authors: Julia Katharina Schwarze, Gil Awada, Louise Cras, Jens Tijtgat, Ramses Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, Bart Neyns
Pages: 1-16 - Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)(2020)
Authors: Gil Awada, Laila Ben Salama, Jennifer De Cremer, Julia Katharina Schwarze, Lydia Fischbuch, Laura Seynaeve, Stephanie Du Four, A Vanbinst, Alex Michotte, Hendrik Everaert, et al.
Pages: 1-12 - An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma(2020)
Authors: Stijn De Keukeleire, Julia Katharina Schwarze, Gil Awada, Hendrik Everaert, A Vanbinst, Louise Cras, Bart Neyns, Sandrine Aspeslagh
Pages: 524-527 - Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab(2020)
Authors: Anne Rogiers, Christophe Leys, Justine Lauwyck, Adrian Schembri, Gil Awada, Julia Katharina Schwarze, Jennifer De Cremer, Peter Theuns, Paul Maruff, Mark De Ridder, et al.